Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 114Neoplasms 37Neoplasm Metastasis 24Stomach Neoplasms 22Pancreatic Neoplasms 19Colonic Neoplasms 15Rectal Neoplasms 13Esophageal Squamous Cell Carcinoma 13Sarcoma 10Esophageal Neoplasms 10Carcinoma, Non-Small-Cell Lung 10Small Cell Lung Carcinoma 8Sarcoma, Ewing 8Breast Neoplasms 8Parkinson Disease 4, Autosomal Dominant Lewy Body 7Glioblastoma 7Ovarian Neoplasms 6Gastrointestinal Neoplasms 6Uterine Cervical Neoplasms 5Solid Tumors 5Recurrence 5Neuroblastoma 5Intestinal Neoplasms 5Digestive System Neoplasms 5Cholangiocarcinoma 5Advanced Solid Tumor 5Rhabdomyosarcoma 4Gastrointestinal Diseases 4Endometrial Neoplasms 4Digestive System Diseases 4

Interventions

regorafenib 1napabucasin 1Oxaliplatin 1Leucovorin 1Irinotecan 1Fluorouracil 1Capecitabine 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Advanced Gastrointestinal Cancer × Irinotecan × Clear all
NCT02024607 2023-11-15

A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer

Sumitomo Pharma America, Inc.

Phase 1/2 Completed
495 enrolled 18 charts
Gastrointestinal

Advanced Gastrointestinal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡